Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red - PubMed (original) (raw)
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red
A Lorenzo et al. Proc Natl Acad Sci U S A. 1994.
Abstract
beta-Amyloid (beta A) is normally produced as a nontoxic soluble peptide. In Alzheimer disease, beta A aggregates and accumulates in the brain as inert diffuse plaques or compact plaques associated with neurodegenerative changes. To determine the relationship of neurotoxicity to the physical state of beta A, we created (i) nonamyloidogenic amorphous aggregates of beta A [amorphous beta A (Am-beta A)] analogous to diffuse plaques and (ii) amyloidogenic fibrils of beta A [fibrillar beta A (Fib-beta A)] analogous to compact plaques. In primary rat hippocampal culture, Fib-beta A was neurotoxic, whereas Am-beta A was not toxic. Fib-beta A caused significant loss of synapses in viable neurons, while Am-beta A had no effect on synapse number. The amyloid fibril-binding dye Congo red inhibited Fib-beta A neurotoxicity by inhibiting fibril formation or by binding to preformed fibrils. Congo red also inhibited the pancreatic islet cell toxicity of diabetes-associated amylin, another type of amyloid fibril. These results indicate that beta A neurotoxicity requires fibril formation. These findings and our previous demonstration that amylin fibrils are toxic suggest that a common cytopathic effect of amyloid fibrils may contribute to the pathogenesis of Alzheimer disease and other amyloidoses.
Similar articles
- Amyloid fibril toxicity in Alzheimer's disease and diabetes.
Lorenzo A, Yankner BA. Lorenzo A, et al. Ann N Y Acad Sci. 1996 Jan 17;777:89-95. doi: 10.1111/j.1749-6632.1996.tb34406.x. Ann N Y Acad Sci. 1996. PMID: 8624132 Review. - Congo red protects against toxicity of beta-amyloid peptides on rat hippocampal neurones.
Burgevin MC, Passat M, Daniel N, Capet M, Doble A. Burgevin MC, et al. Neuroreport. 1994 Dec 20;5(18):2429-32. doi: 10.1097/00001756-199412000-00006. Neuroreport. 1994. PMID: 7696573 - Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer's disease amyloid-beta neurotoxicity.
May PC, Boggs LN, Fuson KS. May PC, et al. J Neurochem. 1993 Dec;61(6):2330-3. doi: 10.1111/j.1471-4159.1993.tb07480.x. J Neurochem. 1993. PMID: 8245987 - Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide.
Milton NG, Harris JR. Milton NG, et al. Micron. 2013 Jan;44:246-53. doi: 10.1016/j.micron.2012.07.001. Epub 2012 Jul 20. Micron. 2013. PMID: 22854213 - Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Walsh DM, et al. Biochem Soc Trans. 2002 Aug;30(4):552-7. doi: 10.1042/bst0300552. Biochem Soc Trans. 2002. PMID: 12196135 Review.
Cited by
- Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer's Pathogenesis.
Almeida ZL, Vaz DC, Brito RMM. Almeida ZL, et al. Mol Neurobiol. 2024 Oct 24. doi: 10.1007/s12035-024-04543-4. Online ahead of print. Mol Neurobiol. 2024. PMID: 39446217 Review. - Protective effects of selegiline against amyloid beta-induced anxiety-like behavior and memory impairment.
Mohamadpour B, Mirazi N, Komaki A, Basir HS, Hosseini A. Mohamadpour B, et al. Brain Behav. 2024 Jun;14(6):e3599. doi: 10.1002/brb3.3599. Brain Behav. 2024. PMID: 38873869 Free PMC article. - Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease.
Zhang W, Smith N, Zhou Y, McGee CM, Bartoli M, Fu S, Chen J, Domena JB, Joji A, Burr H, Lv G, Cilingir EK, Bedendo S, Claure ML, Tagliaferro A, Eliezer D, Veliz EA, Zhang F, Wang C, Leblanc RM. Zhang W, et al. Acta Biomater. 2024 Jul 15;183:341-355. doi: 10.1016/j.actbio.2024.06.001. Epub 2024 Jun 5. Acta Biomater. 2024. PMID: 38849023 - Cacao consumption improves passive avoidance memory impairment in a rat model of Alzheimer's disease: the role of hippocampal synaptic plasticity and oxidative stress.
Basir HS, Mirazi N, Komaki A, Hosseini A. Basir HS, et al. Front Pharmacol. 2024 May 2;15:1379264. doi: 10.3389/fphar.2024.1379264. eCollection 2024. Front Pharmacol. 2024. PMID: 38756381 Free PMC article. - DNA hypomethylation promotes the expression of CASPASE-4 which exacerbates inflammation and amyloid-β deposition in Alzheimer's disease.
Daily KP, Badr A, Eltobgy M, Estfanous S, Whitham O, Tan MH, Carafice C, Krause K, McNamara A, Hamilton K, Houle S, Gupta S, Gupta GA, Madhu S, Fitzgerald J, Saadey AA, Laster B, Yan P, Webb A, Zhang X, Pietrzak M, Kokiko-Cochran ON, Ghoneim HE, Amer AO. Daily KP, et al. Alzheimers Res Ther. 2024 Feb 8;16(1):29. doi: 10.1186/s13195-024-01390-2. Alzheimers Res Ther. 2024. PMID: 38326859 Free PMC article.
References
- Biochem Biophys Res Commun. 1984 May 16;120(3):885-90 - PubMed
- Neurobiol Aging. 1992 Sep-Oct;13(5):609-12 - PubMed
- Nature. 1987 Feb 19-25;325(6106):733-6 - PubMed
- Neurosci Lett. 1989 Nov 6;105(3):294-9 - PubMed
- Science. 1990 Oct 12;250(4978):279-82 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources